Market Overview

UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility

Share:

Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS) with an Equal-weight rating and a $21 price target.

Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the stock valuation appropriately discounts growth outlook … ALKS trades at EV/EBITDA of 21x F13E and 15x F16E (we are focused on F16 because key launches are expected by then). We project 8-yr CAGR (F13-F21E) revenue growth of 6% and EPS growth of 13%. Note ALKS's low tax rate (est. mid-teens long-term) helps justify above average EBITDA multiple."

Alkermes closed at $19.97 on Monday.

Latest Ratings for ALKS

DateFirmActionFromTo
Dec 2020SVB LeerinkMaintainsMarket Perform
Oct 2020MizuhoUpgradesNeutralBuy
Sep 2020B of A SecuritiesMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

 

Related Articles (ALKS)

View Comments and Join the Discussion!

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
GSCitigroupMaintains370.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com